Background:

Thienyldecyl isothiocyanate is a cytochrome P450 inhibitor [1].

The human cytochrome P450 (CYP), a cellular chromophore, has been implicated in metabolism of drugs, arachidonic acid, foreign chemicals, and eicosanoids; steroid synthesis and metabolism; vitamin D3 synthesis and metabolism; cholesterol metabolism and bile-acid biosynthesis; retinoic acid hydroxylation. Until now, there are more than 270 different CYP gene families have been identified, with 18 recorded in mammals. It has been repoted that cytochrome P450 is now understood to include a myriad of enzymic reactions implicated in important life processes. Mutations in many CYP genes result in inborn errors of metabolism and contribute to many clinically relevant diseases [2].

Thienyldecyl isothiocyanate was an analog of thienylbutyl isothiocyanate. Thienyldecyl isothiocyanate showed antiproliferative activity against cancer cells presumably that, like many isothiocyanates. Thienyldecyl isothiocyanate functioned by modulation of xenobiotic-metabolizing enzymes, such as by inhibition of cytochrome P450, and/or by induction of phase II detoxifying enzymes [1].

参考文献:
[1] Yu R, Mandlekar S, Harvey K J, et al.  Chemopreventive isothiocyanates induce apoptosis and caspase-3-like protease activity[J]. Cancer Research, 1998, 58(3): 402-408.
[2] Nebert D W, Russell D W.  Clinical importance of the cytochromes P450[J]. The Lancet, 2002, 360(9340): 1155-1162.